Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001493152-23-001575
Filing Date
2023-01-17
Accepted
2023-01-17 12:59:47
Documents
2
Period of Report
2023-01-05

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 1588
2 ex24.htm EX-24 9027
  Complete submission text file 0001493152-23-001575.txt   12013
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Issuer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 10975 NORTH TORREY PINES ROAD LA JOLLA CA 92037
Business Address
Rupalla Katrin (Reporting) CIK: 0001867590 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41184 | Film No.: 23531009